Potent and Stable Attenuation of Live-HIV-1 by Gain of a Proteolysis-resistant Inhibitor of NF-kappa B (Ikappa B-alpha S32/36A) and the Implications for Vaccine Development*

Ileana QuintoDagger , Massimo MallardoDagger , Francesca BaldassarreDagger parallel , Giuseppe ScalaDagger , George Englund**, and Kuan-Teh Jeang**

From the Dagger  Dipartimento di Biochimica e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", Napoli I-80131, Italy, the ** Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Catanzaro, Catanzaro I-88100 Italy, and the parallel  Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, Maryland 20892-0460

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Live-attenuated human immunodeficiency viruses (HIVs) are candidates for Acquired Immunodeficiency Syndrome (AIDS) vaccine. Based on the simian immunodeficiency virus (SIV) model for AIDS, loss-of-function (e.g. deletion of accessory genes such as nef) has been forwarded as a primary approach for creating enfeebled, but replication-competent, HIV-1/SIV. Regrettably, recent evidence suggests that loss-of-function alone is not always sufficient to prevent the emergence of virulent mutants. New strategies that attenuate via mechanisms distinct from loss-of-function are needed for enhancing the safety phenotype of viral genome. Here, we propose gain-of-function to be used simultaneously with loss-of-function as a novel approach for attenuating HIV-1. We have constructed an HIV-1 genome carrying the cDNA of a proteolysis-resistant nuclear factor-kappa B inhibitor (Ikappa B-alpha S32/36A) in the nef region. HIV-1 expressing Ikappa B-alpha S32/36A down-regulates viral expression and is highly attenuated in both Jurkat and peripheral blood mononuclear cells. We provide formal proof that the phenotypic and attenuating characteristics of Ikappa B-alpha S32/36A permit its stable maintenance in a live, replicating HIV-1 despite 180 days of forced ex vivo passaging in tissue culture. As compared with other open-reading frames embedded into HIV/SIV genome, this degree of stability is unprecedented. Thus, Ikappa B-alpha S32/36A offers proof-of-principle that artifactually gained functions, when used to attenuate the replication of live HIV-1, can be stable. These findings illustrate gain-of-function as a feasible strategy for developing safer live-attenuated HIVs to be tested as candidates for AIDS vaccine.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Live-attenuated human immunodeficiency virus, type-1 (HIV-1)1 viruses are vaccine candidates for AIDS based on the assumption that poorly replicating viruses are reduced in cytopathicity while eliciting an efficient immune response in vivo. In fact, in the SIV model of AIDS, viruses deleted of accessory genes, such as nef, are attenuated and confer immune protection in adults (1-6). Recent results have raised concerns about the safety of such live-attenuated viruses because of the emergence of virulent mutants (7-11). Hence, it is reasonable that new mechanistically distinct strategies should be considered in combination with loss-of-function to develop safe live-attenuated vaccine candidates. Stable attenuation of lentivirus is difficult. Reasons for this include the high mutability of retroviruses as a consequence of poor fidelity in reverse transcription and high rates of viral replication. Virus replication is one of several parameters used to measure HIV disease progression. To this end, endowing the viral genome with an inhibitory function that represses replication is, in principle, a valid strategy for attenuation.

AIDS pathogenesis involves complex host-pathogen interactions (12-17). HIV-1 entry occurs through binding of gp120 envelope glycoprotein to CD4 and chemokine co-receptors (18, 19). Later, after reverse transcription and integration, regulated HIV-1 gene expression is dependent on cellular transcription factors and on the viral Tat protein acting through several cis regulatory sequences in the HIV-1 LTR (20, 21). Prominent among these sequences are two NF-kappa B sites located upstream of the Sp1-TATAA motif (22) and a third NF-kappa B site co-incident with the TAR sequence (23). The prevalence of NF-kappa B sites in all HIV isolates (24) suggests that NF-kappa B function is fundamentally important for virus replication and represents an attractive target to attenuate HIVs. NF-kappa B is regulated by Ikappa B inhibitors (25). In response to activating stimuli, Ikappa B proteins become phosphorylated, ubiquinated, and degraded by proteasomes. This releases active NF-kappa B complexes leading to transcriptional activation of responsive genes. An Ikappa B-alpha mutant protein, Ikappa B-alpha S32/36A (defective for serine 32- and serine 36-phosphorylation), was previously shown to resist proteolysis (26, 27). Ikappa B-alpha S32/36A was found to be a particularly potent inhibitor of NF-kappa B-dependent gene transcription (26, 27). Based on the role of NF-kappa B in virus transcription, we reasoned that expression of Ikappa B-alpha S32/36A could be one way to attenuate HIV-1.

Here, we have investigated the feasibility of a stable bimodal attenuation of HIV-1 through both gain- and loss-of-function. We show that a proteolysis-resistant dominant negative Ikappa B-alpha molecule (Ikappa B-alpha S32/36A) can be inserted into nef of HIV-1, is maintained in the viral genome despite prolonged passaging in tissue culture, and contributes to a strong attenuation of HIV-1. These results indicate that gain-of-function should be considered together with loss-of-function in strategies for constructing safe live-attenuated HIV-1 vaccine candidates. In addition, they demonstrate that NF-kappa B inhibition is a major target for HIV-1 attenuation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Construction of Ikappa B-alpha Recombinant HIV-1 Viruses-- pNLDelta nef was generated by replacing the first 117 nucleotides of nef sequence of pNL4-3 (28) with a linker specifying for the unique restriction sites XhoI, XbaI, and NotI. This resulted in the frameshift of the remaining nef sequence. cDNAs for Ikappa B-alpha and Ikappa B-alpha S32/36A were amplified by PCR using a 5'-primer flanked by SalI site and a 3'-primer flanked by the FLAG sequence followed by stop codon and XbaI site. The 5'-primer was 5'-ACGCGTCGACATGTTCCAGGCGGCCGAGCGC-3'; the 3'-primer was 5'-GCTCTAGATCACTTGTCGTCATCGTCTTTGTAGTCTAACGTCAGACGCTGGCCTCCAAA-3'. The PCR products for Ikappa B-alpha and Ikappa B-alpha S32/36A were digested with SalI and XbaI and ligated into pNLDelta nef to generate pNLIkappa B-wt and pNLIkappa B-M, respectively. Ikappa B-alpha S32/36A was also cloned in antisense orientation using a 5'-primer flanked by XbaI site and a 3'-primer flanked by SalI site to generate pNLIkappa B-as. Molecular clones were confirmed by DNA restriction analysis and DNA sequencing.

Transfections and Viral Stocks-- 293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% v/v heat-inactivated fetal bovine serum and 3 mM glutamine. Viral stocks were produced by transfecting 293T cells (5 × 106) with viral plasmids (10 µg) using calcium phosphate. Forty hours later, the cell culture supernatant was passed through a 0.45-µm filter and measured for RT activity.

Immunoblot Analysis-- 293T cells were transfected with viral plasmids (10 µg) and were lysed in RIPA buffer 24 h later. Proteins (10 µg) were separated by electrophoresis in 10% SDS-polyacrylamide gel and transferred to Immobilon-P (Millipore). Filters were blotted with AIDS patient serum or with anti-FLAG monoclonal antibody (Eastman Kodak, Rochester, NY) and anti-Ikappa B-alpha antiserum recognizing the amino acids 51-64 of Ikappa B-alpha (gift from N. Rice, National Cancer Institute-Frederick Cancer Research and Development Center, MD) using Western-Light Chemiluminescent Detection System (Tropix, Bedford, MA).

RNase Protection Assay-- 293T cells were transfected with viral plasmids (10 µg) using calcium phosphate, and total RNA was isolated by acid guanidinium thiocyanate/phenol/chloroform extraction 3 days after transfection. RNA was treated with RQ1 DNase from Promega (2 units/50 µg of RNA) at 37 °C for 15 min, extracted by phenol:chloroform (25:24) and precipitated in ethanol. RNase protection assay was performed using RPA II kit (Ambion, Austin, TX). Briefly, aliquots of 10 µg of RNA from different samples were hybridized with 105 cpm of HIV-1 and actin RNA probes for 15 h at 44 °C. Yeast RNA was used as control. Samples were treated with RNase A (2.5 units/ml) and RNase T1 (100 units/ml) for 30 min at 37 °C, precipitated in ethanol, resuspended in gel loading buffer (95% formamide, 0.025% xylene cyanol, 0.025% bromphenol blue, 0.5 mM EDTA, 0.025% SDS), and separated by electrophoresis on 8 M urea, 8% acrylamide gel in Tris borate-EDTA. HIV-1 antisense probe to the pNL4-3 sequence from +350 to +535 nt corresponding to NF-kappa B, Sp1, TATAA, and TAR sequences of HIV-1 LTR was transcribed from the T7 promoter in the pGEM LTR vector. Protected HIV-1-specific bands of 80 and 185 bp correspond to the 5'-LTR (+455 to +535 nt of pNL4-3 sequence) and the 3'-LTR (+9425 to +9610 nt of pNL4-3 sequence), respectively. Actin antisense probe was transcribed using T7 RNA-polymerase from vector pTRI-beta -actin-125-human (Ambion). Protected actin transcript corresponds to a band of 127 bp. T7 RNA polymerase-derived transcripts were produced by using the Riboprobe in vitro Transcription System (Promega). Transfection efficiencies were normalized to CAT activity measured from co-transfections with pBLCAT2 (2 µg), which contains the cat gene fused to the herpes simplex virus tk minimal promoter, followed by CAT assay (23).

Luciferase Assay-- Jurkat cells (2 × 106) were co-transfected with pNL-Luc-R-E- plasmid (29) (1 µg) and pNLIkappa B-as or pNLIkappa B-M plasmids (5 µg) using Superfect Reagent (Qiagen, Valencia, CA). Amounts of transfected DNA were equalized with pcDNA3.1 (Stratagene, La Jolla, CA). Transfected cells were cultured in RPMI supplemented with 10% v/v heat-inactivated fetal bovine serum and 3 mM glutamine with soluble CD4 (10 µg/ml) to inhibit multiple rounds of infection. Cell extracts were prepared at 24, 48, and 72 h post-transfection and analyzed for luciferase activity using Luciferase Assay System (Promega).

Viral Growth-- Jurkat cells were cultured in RPMI supplemented with 10% v/v heat-inactivated fetal bovine serum and 3 mM glutamine. PBMCs were stimulated with PHA (0.5 µg/ml) or mAb OKT3 (1 µg/ml) in RPMI 1640 with 10% v/v heat-inactivated fetal bovine serum for 3 days and then washed and cultured in RPMI 1640 with 10% fetal bovine serum with interleukin-2 (20 units/ml). Cells were infected with equivalent doses of viral stocks normalized by RT activity. Cell supernatants were collected every 3 days for RT assay; equal volumes of fresh medium were replaced into the cultures at the same time.

RT-PCR Analysis-- Viral RNA was purified from cell culture supernatants using QIAampViral RNA kit (Qiagen). RNA extracts (1 µg) were reverse transcribed, and PCR was amplified using Titan One Tube RT-PCR System (Roche Molecular Biochemicals). The Ikappa B-alpha S32/36A sequence was amplified with primers flanking the cDNA insert from +8732 to +8749 nt (5'-primer; env region) and from +9017 to +9034 nt (3'-primer; nef region) of pNL4-3. As control, the integrase region was amplified with 5'-primer from +4339 to +4359 nt and 3'-primer from +4894 to +4914 nt of pNL4-3. Amplification was carried out according to the following protocol: incubation at 50 °C for 30 min, preheating at 95 °C for 2 min followed by 30 cycles of 95 °C for 45 s, 58 °C for 45 s, and 72 °C for 3 min.

Flow Cytometry Analysis-- Cells were stained with phycoerythrin-conjugated anti-p24 mouse monoclonal antibody (Ortho Diagnostic, Raritan, NJ) and Annexin-V-Fluos (Roche Molecular Biochemicals). Flow cytometry was performed with a Coulter Epics XL Cytometer. Ten thousands cells were analyzed under each condition.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

HIV-1 Expressing Ikappa B-alpha S32/36A Down-regulates Viral Expression-- To determine whether the attenuation of HIV-1 could be obtained via cis-expression of a proteolysis-resistant inhibitor of NF-kappa B, FLAG-tagged Ikappa B-alpha S32/36A cDNA was positioned in sense and antisense orientations into nef of HIV-1 pNL4-3 generating pNLIkappa B-M and pNLIkappa B-as genomes, respectively (Fig. 1A). As a control, an otherwise isogenic molecular clone of pNL4-3 expressing the proteolysis-sensitive wild-type Ikappa B-alpha (pNLIkappa B-wt) cDNA was also constructed (Fig. 1A). These insertions also resulted in the deletion of 39 amino acids from the N terminus of Nef and a translational frameshift for the remaining Nef-encoding codons. Hence, the chimeric genomes gained an Ikappa B-alpha S32/36A function coupled with a simultaneous loss of Nef function. From these molecular genomes, different virus stocks were generated through independent transfections of 293T cells. Expression in the transfected cells of HIV-1 proteins and the heterologous Ikappa B-cDNAs was verified by immunoblotting (Fig. 1, B and C). To assess the functional impact of Ikappa B-alpha S32/36A in the context of HIV-1 gene expression, viral transcription in 293T cells transfected individually with pNL4-3, pNLDelta nef, pNLIkappa B-M, pNLIkappa B-as, or pNLIkappa B-wt was analyzed by RNase protection assays. Viral RNAs were efficiently produced from all genomes except for the Ikappa B-alpha S32/36A-expressing virus, pNLIkappa B-M (Fig. 2A). This finding points to a strong inhibition of LTR-directed transcription by Ikappa B-alpha S32/36A. A normalized simultaneous co-transfection into cells of pNLIkappa B-M genome with pNL4-3 genome fused to the luciferase reporter gene still resulted in markedly reduced viral transcription (Fig. 2B). The inhibitory mechanism is likely to be a dominant trans-repressive effect from the Ikappa B-alpha S32/36A protein rather than a cis-destabilizing phenomenon arising as a consequence of an insertion into nef. This is further supported by the fact that the insertion of Ikappa B-alpha cDNA either in antisense orientation, or as wild-type sequence does not inhibit viral expression (Fig. 2A, lanes 7 and 8). Repressed expression would have been expected if there were a cis insertional effect.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Recombinant HIV-1 viruses that express Ikappa B-alpha . Panel A, structure of HIV-1 genomes that express Ikappa B-alpha wild-type (pNLIkappa B-wt), Ikappa B-alpha S32/36A in sense (pNLIkappa B-M), and antisense (pNLIkappa B-as) orientations, respectively. Panel B, immunoblot analysis of total extracts (10 µg each) from 293T cells 24 h after transfection with the indicated HIV-1 plasmids (10 µg) using a hyperimmune AIDS patient serum. Panel C, immunoblot analysis of total extracts (10 µg) from 293T cells 24 h after transfection with the indicated HIV-1 plasmids (10 µg) using anti-FLAG monoclonal antibody followed by an anti-Ikappa B-alpha antiserum. This mixture identifies both Ikappa B-alpha -FLAG expressed from the viral genomes and endogenous Ikappa B-alpha .


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Ikappa B-alpha S32/36A represses HIV-1 LTR-directed transcription. Panel A, 293T cells were transfected with the indicated viral plasmids (10 µg). Transfection efficiencies were normalized based on the co-transfection with 2 µg of pBLCAT2. Total RNAs were quantitated by RNase protection assay 72 h after transfection. Viral RNAs were measured as 3'-LTR and 5'-LTR protected fragments. Cellular actin-mRNA was quantitated in parallel. Lane 1, RNA probe plus yeast RNA; lane 2, RNase treatment of RNA probe plus yeast RNA; lane 3, RNase treatment of RNA probe plus RNA from cells transfected only with pBLCAT2. Lanes 4-8, RNase treatment of RNA probe plus RNA from cells transfected with pNL4-3 (lane 4), pNLDelta nef (lane 5), pNLIkappa B-M (lane 6), pNLIkappa B-as (lane 7), and pNLIkappa B-wt (lane 8). Lane 9, sample as in lane 6 with a 10-fold longer exposure. CAT activities, measured as percent acetylation of [14C]chloramphenicol per 50 µg of protein per 3 h, from lane 3-8 were: 1.5, 1.7, 1.0, 1.6, 1.2, and 1.9, respectively. Results are representative of three independent experiments. Panel B, Jurkat cells were transfected with pcDNA3.1, pNLIkappa B-as, or pNLIkappa B-M plasmids (5 µg) together with pNL-Luc-R-E- reporter plasmid (1 µg). Luciferase assay was performed in cell lysates at the indicated time. Luciferase activity is expressed as arbitrary light units per 100 µg of protein. Results are representative of three independent experiments.

Attenuation of HIV-1 Expressing Ikappa B-alpha S32/36A-- Next, the replication properties of the recombinant HIV-1 genomes were measured. We monitored for viral growths in established (Jurkat) and primary (PBMCs) T-cells. Based on normalized amounts of input viruses, NLIkappa B-M was found to be highly attenuated in Jurkat cells when compared with the NLDelta nef and NLIkappa B-as (Fig. 3A). A reduced replication capacity was also observed for NLIkappa B-M in human PBMCs stimulated either with anti-CD3 mAb OKT3 (Fig. 3B) or PHA (Fig. 3C). In parallel, the chimeric HIV-1 which expresses the proteolysis-sensitive wild-type Ikappa B-alpha produced a replication profile that was only slightly attenuated when compared with control NLIkappa B-as virus (Fig. 4, A-C). Taken together, these results indicate a critical contribution of proteolysis-resistant mutant Ikappa B-alpha toward attenuated viral growth.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   HIV-1 expressing Ikappa B-alpha S32/36A is highly attenuated in Jurkat cells and human PBMCs. Panel A, Jurkat (5 × 104) cells were infected with NL4-3, NLDelta nef, NLIkappa B-M, and NLIkappa B-as with equal amounts of viruses normalized based on RT counts of 104 cpm (left) or 103 cpm (right). Panel B, PBMCs (2 × 105 cells) stimulated with mAb OKT3 were infected with the indicated viruses normalized for 105 cpm (left) or 104 cpm (right) of RT. Panel C, PBMCs (2 × 105 cells) stimulated with PHA were infected with viruses normalized for 104 cpm (left) or 103 cpm (right) of RT. Viral growth was measured by RT activity in cell culture supernatants. Results representative of six independent infections are shown.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   Wild-type proteolysis-sensitive Ikappa B-alpha poorly attenuates HIV-1 replication. Jurkat cells (panel A), PBMCs stimulated with mAb OKT3 (panel B), and PBMCs stimulated with PHA (panel C) were infected with NLIkappa B-M, NLIkappa B-as, or NLIkappa B-wt viruses and measured for viral production as detailed in Fig. 3.

Attenuation of NLIkappa B-M Is Not Because of Apoptosis-- Previously, Ikappa B-alpha S32/36A was shown to enhance the apoptosis induced by tumor necrosis factor-alpha (30-32). Because tumor necrosis factor-alpha is produced during HIV-1 infection (33, 34), we asked whether a pro-apoptotic effect of Ikappa B-alpha S32/36A might account, in part, for attenuation of viral growth. To this end, Jurkat cells infected separately with NL4-3, NLIkappa B-M, or NLIkappa B-as viruses were analyzed by flow cytometry for the expression of p24 and for binding to annexin V, a marker of an early event in apoptosis (35). Because of the different viral growth kinetics, to account fully for equivalent levels of virus production, cell samples were analyzed at variant times post-infection. As shown in Table I, the percentage of apoptotic cells among p24-positive population was 17 and 13% for NL4-3 and NLIkappa B-as, respectively, at day 10 post-infection, as compared with 19% for NLIkappa B-M at day 18 post-infection. Thus, the expression of Ikappa Balpha S32/36A did not affect apoptosis significantly because the percentage of apoptotic cells among those infected with NL4-3, NLIkappa B-as, or NLIkappa B-M was similar.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Flow cytometric analysis of Jurkat cells infected with NL4-3, NLIkappa B-as, or NLIkappa B-M
The cells were analysed by flow cytometry for the expression of p24, as marker of viral infection, and for binding to annexin V, as marker of apoptosis. Ten thousand cells were analysed under each condition. Values are expressed as percentages.

NLIkappa B-M Is Stably Attenuated through Cell Passaging-- Retroviruses rapidly delete heterologous genes which do not confer benefits for replication (36-38). One indication of such a loss in gained function would be a change in the kinetics of replication in later (compared with earlier) passages of viruses. In examining NLIkappa B-M virus after prolonged culturing in cells, we noted that its attenuated phenotype bred true despite extended re-passaging (Fig. 5, A-C). No changes in replication phenotype were observed with up to 180 days (9 passages) of continuously forced propagation in ex vivo tissue cultures. This stability of Ikappa B-alpha S32/36A contrasts sharply with documented findings in other systems where rapid deletion of gained function commenced as early as 48 h after viral passaging (36). To verify biochemically that this phenotypic stability was from the maintenance of Ikappa B-alpha S32/36A in nef, RT-PCR analysis of virion RNAs was performed using samples isolated after various times of culturing in Jurkat cells (Fig. 5D). Viral RNAs from first passage (20 days in culture) as compared with sixth (120 days in culture) and ninth (180 days in culture) passage were indistinguishable, providing no evidence for deletion of Ikappa B-alpha S32/36A (Fig. 5D, compare lanes 5-7). Thus, by contrast with other cDNAs inserted into nef (36-38) in the setting of replicating HIV-1/SIV, Ikappa B-alpha S32/36A is unprecedently stable.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 5.   NLIkappa B-M virus maintains an attenuated phenotype through serial passaging. Jurkat (panel A), PBMCs stimulated with mAb OKT3 (panel B), and PBMCs stimulated with PHA (panel C) were infected with NLIkappa B-as, NLIkappa B-M, or passaged NLIkappa B-M viruses and measured for viral production as detailed in Fig. 3. NLIkappa B-M virus was obtained through serial passages in Jurkat cells by collecting the RT peak of viral production at each passage. On average, each passage was for 20 days. Panel D, RT-PCR analysis of nef and integrase regions of NLIkappa B-M virion RNAs. The wild-type nef product (302 bp; lane 2), the Delta nef product (200 bp; lane 3), the Ikappa B-alpha S32/36A product (1180 bp; lanes 4-7), and the integrase product (575 bp; lanes 9-14) were visualized by RT-PCR of viral RNA. Lane 1, 100-bp DNA ladder (Life Technologies, Inc.); lanes 2 and 9, amplification of NL4-3 virion RNAs from 293T transfected with pNL4-3. Lanes 3 and 10, amplification of NLDelta nef virion RNAs from 293T transfected with pNLDelta nef; lanes 4 and 11, amplification of NLIkappa B-M virion RNAs from 293T transfected with pNLIkappa B-M; lanes 5 and 12, amplification of NLIkappa B-M virion RNAs from first passage in Jurkat; lanes 6 and 13, amplification of NLIkappa B-M virion RNAs from sixth passage in Jurkat; lanes 7 and 14, amplification of NLIkappa B-M virion RNAs from ninth passage in Jurkat; lanes 8 and 15, RT-negative controls.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Various approaches have been proposed for generating live-attenuated HIV-1 (39). Based on findings from the SIV model of AIDS, loss-of-function (e.g. deletion of accessory genes such as nef, vpr, and U3) has been forwarded as a primary approach for creating enfeebled, but replication-competent, HIV/SIV (1-6). Regrettably, recent evidence indicates that loss-of-function alone is not always sufficient (and is perhaps largely insufficient) to prevent virulence (7-11). Hence, one is faced with either abandoning live-attenuated virus as a potential route for HIV-1 vaccine or devising another approach which is mechanistically distinct from and could be used additively with loss-of-function in attenuating the AIDS virus. Attenuation of HIV-1 by gain-of-function was first broached four years ago (40). However, an issue that has impeded the useful application of gain-of-function is uncertainty over the stability of functions added to a replicating HIV-1 genome. To date, all exogenous open-reading frames, such as thymidine kinase, gamma -interferon, interleukin-2 (36-38), when artifactually embedded into the HIV-1/SIV genome have been unstable to prolonged ex vivo passaging, suggesting a rule of rapid deletion of gained genes upon virus replication. However, because the sampling size for gained functions has been small, it remains unclear whether this is indeed a universal rule. Our findings from Ikappa B-alpha S32/36A formally challenge the rigidity of this rule.

An ability by viruses in general and by HIV-1 specifically to maintain stably gained functions should not be inherently surprising. For example, piracy of large numbers of cellular genes by herpesviruses has been well documented (see Ref. 41 and references cited therein). In simple animal retroviruses, only Gag, Pol, and Env open-reading frames are required for virus propagation. Hence, the evolution of tat, rev, nef, vpu, vif, and vpr in the existing HIV-1 genome represents likely illustrations of how this virus has anciently through natural means acquired and continues to maintain stably added reading frames. Conceivably, Ikappa B-alpha S32/36A has certain cellular characteristics that benefit the virus-cell interaction during HIV-1 replication. What might be the propitious characteristics specified by Ikappa B-alpha S32/36A await further investigation. It is possible that the inhibition of virus transcription by Ikappa B-alpha S32/36A allows the cell to survive HIV-1 infection, while cell killing occurs in the case of recombinant viruses that carry exogenous genes which do not confer virus attenuation. A second possible explanation for the insert stability in NLIkappa B-M is that Ikappa B-alpha S32/36A could provide an "anti-mutator" effect to the chimeric HIV-1 genome. This "anti-mutator" effect would confer a relative resistance to the deletion of the gained function. In this regard, the expression of a dominant negative Ikappa B-alpha has been shown to correct aberrant DNA synthesis which causes genetic instability in ataxia telangectasia cells (42).

In conclusion, we demonstrate here the feasibility of a gain-of-function strategy for stably attenuating live HIV-1. Specifically, we show that the addition of Ikappa B-alpha S32/36A to an HIV-1 genome conferred a highly attenuated replication phenotype that is genetically stable for a minimum of 180 days of growth in tissue culture. Attenuated replication in ex vivo tissue culture is by no means a perfect predictor of in vivo viral robustness; however, the unprecedented observation that emerges from Ikappa B-alpha S32/36A is its durability in settings where other artifactually gained open-reading frames (36-38) have failed. An important extension to the experiments here would be to explore the in vivo stability of Ikappa B-alpha S32/36A in chimeric SIVs propagated in macaques. However, the fact that transcription from the SIV LTR is not ruled by NF-kappa B in the same manner as that from the HIV-1 LTR (43-45) undermines the feasibility of such a heterologous in vivo test for Ikappa B-alpha S32/36A. In this regard, further studies on SIV LTR-driven transcription are warranted to identify analogous cellular inhibitors of SIV replication. That not withstanding, the findings from Ikappa B-alpha S32/36A represent a first-step proof that gain-of-function could be a stably useful approach for attenuation. This first step should spur further stepwise exploration for other useful attenuating markers that might be more amenable to incremental testing in nonhuman primate models. If so, a combination approach that incorporates gain-of-function with loss-of-function could possibly contribute toward the development of a live-attenuated HIV-1 vaccine.

    FOOTNOTES

* This work was supported by Ministero della Sanità-Istituto Superiore di Sanità-Programma Nazionale di Ricerca sull`AIDS Grant 40A.0.85, by Pediatric AIDS Foundation Grant PS-22055, and by the AIDS Antiviral Targeted program from the Office of the Director, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel Recipient of a fellowship from Istituto Superiore di Sanità-Progetto di Ricerche sull'AIDS.

To whom correspondence should be addressed: Dipartimento di Biochimica E Biotecnologie Mediche, via Sergio Pansini 5, I-80131 Napoli, Italy. Tel.: 39-081-7463157; Fax: 39-081-7463150; E-mail: quinto{at}dbbm.unina.it

    ABBREVIATIONS

The abbreviations used are: HIV-1, human immunodeficiency virus, type-1; SIV, simian immunodeficiency virus; AIDS, acquired immunodeficiency syndrome; LTR, long terminal repeat; NF-kappa B, nuclear factor kappa B; RT, reverse transcriptase; PCR, polymerase chain reaction; PBMC, peripheral blood mononuclear cell; CAT, chloramphenicol acetyltransferase; PHA, phytohemagglutinin; nt, nucleotide(s); bp, base pair(s); mAb, monoclonal antibody.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Daniel, M. D., Kirchhoff, F., Czajak, S. C., Sehgal, P. K., and Desrosiers, R. C. (1992) Science 258, 1938-1941[Medline] [Order article via Infotrieve]
  2. Almond, N., Kent, K., Cranage, M., Rud, E., Clarke, B., and Stott, E. J. (1995) Lancet 345, 1342-1344[CrossRef][Medline] [Order article via Infotrieve]
  3. Wyand, M. S., Manson, K. H., Garcia-Moll, M., Montefiori, D., and Desrosiers, R. C. (1996) J. Virol. 70, 3724-3733[Abstract]
  4. Beer, B., Baier, M., zur Megede, J., Norley, S., and Kurth, R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4062-4067[Abstract/Free Full Text]
  5. Shibata, R., Siemon, C., Czajak, S. C., Desrosiers, R. C., and Martin, M. A. (1997) J. Virol. 71, 8141-8148[Abstract]
  6. Desrosiers, R. C., Lifson, J. D., Gibbs, J. S., Czajak, S. C., Howe, A. Y., Arthur, L. O., and Johnson, R. P. (1998) J. Virol. 72, 1431-1437[Abstract/Free Full Text]
  7. Baba, T. W., Jeong, Y. S., Pennick, D., Bronson, R., Greene, M. F., and Ruprecht, R. M. (1995) Science 267, 1820-1825[Medline] [Order article via Infotrieve]
  8. Wyand, M. S., Manson, K. H., Lackner, A. A., and Desrosiers, R. C. (1997) Nat. Med. 3, 32-36[Medline] [Order article via Infotrieve]
  9. Cohen, J. (1997) Science 278, 24-25[Free Full Text]
  10. Berkhout, B., Verhoef, K., van Wamel, J. L. B., and Back, N. K. T. (1999) J. Virol. 73, 1138-1145[Abstract/Free Full Text]
  11. Baba, T. W., Liska, V., Khimani, A. H., Ray, N. B., Dailey, P. J., Penninck, D., Bronson, R., Greene, M. F., McClure, H. M., Martin, L. N., and Ruprecht, R. M. (1999) Nat. Med. 5, 194-203[CrossRef][Medline] [Order article via Infotrieve]
  12. Coffin, J. M. (1995) Science 267, 483-489[Medline] [Order article via Infotrieve]
  13. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., and Ho, D. D. (1996) Science 271, 1582-1586[Abstract]
  14. Fauci, A. S. (1996) Nature 384, 529-534[CrossRef][Medline] [Order article via Infotrieve]
  15. Finzi, D., and Siliciano, R. F. (1998) Cell 93, 665-671[Medline] [Order article via Infotrieve]
  16. Douek, D. C., McFarland, R. D., Keiser, P. H., Gage, E. A., Massey, J. M., Haynes, B. F., Polis, M. A., Haase, A. T., Feinberg, M. B., Sullivan, J. L., Jamieson, B. D., Zack, J. A., Picker, L. J., and Koup, R. A. (1998) Nature 396, 690-695[CrossRef][Medline] [Order article via Infotrieve]
  17. Marx, P. A., and Chen, Z. (1998) Semin. Immunol. 10, 215-223[CrossRef][Medline] [Order article via Infotrieve]
  18. Littman, D. R. (1998) Cell 93, 677-680[Medline] [Order article via Infotrieve]
  19. Rizzuto, C. D., Wyatt, R., Hernandez-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A., and Sodroski, J. (1998) Science 280, 1949-1953[Abstract/Free Full Text]
  20. Roulston, A., Lin, R., Beauparlant, P., Wainberg, M. A., and Hiscott, J. (1995) Microbiol. Rev. 59, 481-505[Abstract]
  21. Berkhout, B., Silverman, R., and Jeang, K-T. (1989) Cell 53, 273-282
  22. Nabel, G., and Baltimore, D. (1987) Nature 326, 711-713[CrossRef][Medline] [Order article via Infotrieve]
  23. Mallardo, M., Dragonetti, E., Baldassarre, F., Ambrosino, C., Scala, G., and Quinto, I. (1996) J. Biol. Chem. 271, 20820-20827[Abstract/Free Full Text]
  24. Myers, G., Korber, B., Foley, B., Jeang, K. T., Mellors, J. W., and Wain-Hobson, S. (eds) (1996) Human Retroviruses and AIDS, p. I-3, Los Alamos National Laboratory, Theoretical Biology and Biophysics Group T-10, Los Alamos, NM
  25. Ghosh, S., May, M. J., and Kopp, E. B. (1998) Annu. Rev. Immunol. 16, 225-260[CrossRef][Medline] [Order article via Infotrieve]
  26. Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist, U. (1995) Science 267, 1485-1488[Medline] [Order article via Infotrieve]
  27. Brockman, J. A., Scherer, D. C., McKinsey, T. A., Hall, S. M., Qi, X., Lee, W. Y., and Ballard, D. W. (1995) Mol. Cell. Biol. 15, 2809-2818[Abstract]
  28. Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., and Martin, M. A. (1986) J. Virol. 59, 284-291[Medline] [Order article via Infotrieve]
  29. Connor, R. I., Chen, B. K., Choe, S., and Landau, N. R. (1995) Virology 206, 935-944[CrossRef][Medline] [Order article via Infotrieve]
  30. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  31. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. (1996) Science 274, 784-787[Abstract/Free Full Text]
  32. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
  33. Wright, S. C., Jewett, A., Mitsuyasu, R., and Bonavida, B. (1988) J. Immunol. 141, 99-104[Abstract/Free Full Text]
  34. Poli, G., Kinter, A., Justement, J. S., Kehrl, J. H., Bressler, P., Stanley, S., and Fauci, A. S. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 782-785[Abstract]
  35. Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van Schie, R. C., LaFace, D. M., and Green, D. R. (1995) J. Exp. Med. 182, 1545-1556[Abstract]
  36. Smith, S. M., Markham, R. B., and Jeang, K. T. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7955-7960[Abstract/Free Full Text]
  37. Giavedoni, L. D., and Yilma, T. (1996) J. Virol. 70, 2247-2251[Abstract]
  38. Gundlach, B. R., Linhart, H., Dittmer, U., Sopper, S., Reiprich, S., Fuchs, D., Fleckenstein, B., Hunsmann, G., Stahl-Hennig, C., and Uberla, K. (1997) J. Virol. 71, 2225-2232[Abstract]
  39. Letvin, N. L. (1998) Science 280, 1875-1880[Abstract/Free Full Text]
  40. Kestler, H. W., and Jeang, K. T. (1995) Science 270, 1219[Medline] [Order article via Infotrieve]
  41. Nicholas, J., Ruvolo, V., Zong, J., Ciufo, D., Guo, H. G., Reitz, M. S., and Hayward, G. S. (1997) J. Virol. 71, 1963-1974[Abstract]
  42. Jung, M., Zhang, Y., Lee, S., and Dritschilo, A. (1995) Science 268, 1619-1621[Medline] [Order article via Infotrieve]
  43. Ilyinskii, P. O., Simon, M. A., Czajak, S. C., Lackner, A. A., and Desrosiers, R. C. (1997) J. Virol. 71, 1880-1887[Abstract]
  44. Zhang, J., Novembre, F., and Rabson, A. B. (1997) Virus Res. 49, 205-213[CrossRef][Medline] [Order article via Infotrieve]
  45. Pohlmann, S., Floss, S., Ilyinskii, P. O., Stamminger, T., and Kirchhoff, F. (1998) J. Virol. 72, 5589-5598[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.